DexTech Medical AB (XSAT:DEX) Interest Expense : kr0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. DexTech Medical AB's interest expense for the three months ended in Dec. 2024 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. DexTech Medical AB's Operating Income for the three months ended in Dec. 2024 was kr -1.57 Mil. DexTech Medical AB's Interest Expense for the three months ended in Dec. 2024 was kr 0.00 Mil. DexTech Medical AB has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

DexTech Medical AB Interest Expense Historical Data

The historical data trend for DexTech Medical AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB Interest Expense Chart

DexTech Medical AB Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Interest Expense

Get a 7-Day Free Trial

DexTech Medical AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

DexTech Medical AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

DexTech Medical AB (XSAT:DEX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

DexTech Medical AB's Interest Expense for the three months ended in Dec. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was kr-1.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was kr0.00 Mil.

DexTech Medical AB's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

DexTech Medical AB had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

DexTech Medical AB has no debt.

DexTech Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37

Website

https://www.dextechmedical.com

DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.